Trial Profile
CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Crizotinib
- Indications Solid tumours
- Focus Adverse reactions; Expanded access
- Sponsors Pfizer
- 14 Mar 2024 This trial has been completed in Germany, Italy, and Hungary, according to European Clinical Trials Database.
- 25 Sep 2023 Status changed from active, no longer recruiting to completed.
- 17 Jun 2020 Planned End Date changed from 31 May 2021 to 1 May 2022.